(Sharecast News) - Biotech firm Graft Polymer said on Monday that it has agreed to buy Awakn Life Sciences Corp, a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, for £4.98m.
Awakn has a near-term focus on alcohol use disorder (AUD), a condition affecting about 29m adults...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE